Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease
Blood Coagulation and Fibrinolysis, Volume 21, No. 7, Year 2010
Notification
URL copied to clipboard!
Description
Platelet glycoprotein IIb/IIIa is a membrane receptor which plays a key role in coronary artery disease and thrombotic events. However, there is a considerable controversy regarding the clinical impact of glycoprotein IIIa platelet antigen 1 (PlA1)/platelet antigen 2 (PlA2) polymorphism as a risk factor for myocardial infarction. To evaluate the association between glycoprotein IIIa PlA1/PlA2 polymorphism and 1-year cardiovascular events occurrence in aspirin-treated patients with stable coronary artery disease. We prospectively included 188 postacute coronary syndrome patients (183 men) aged 59 ± 10 years and receiving aspirin (250 mg/day). The clinical outcome at 1 year was the composite end point of nonfatal myocardial infarction, stroke, recurrent unstable angina or cardiac death. Genotyping for PlA1/PlA2 polymorphism was conducted using PCR and restriction fragment length polymorphism analysis. The genotype distribution of glycoprotein IIIa PlA1/PlA2 polymorphism was PlA1/PlA1, 55.3%; PlA1/PlA2, 39.3% and PlA2/PlA2, 4%. Incidence of composite end point in homozygous PlA1/PlA1 carriers was significantly higher than in PlA2/PlA2 and PlA1/PlA2 patients [14.4 vs. 3.6% odds ratio 4.5 (1.2-16.6, 95% confidence interval); P = 0.012]. Multivariate analysis identified three strong predictive factors of cardiac death: age more than 65 years [odds ratio = 6.8, (1.4-34, 95% confidence interval); P = 0.018], ventricular ejection fraction less than 50% [odds ratio = 8.6, (1.7-42.6, 95% confidence interval); P = 0.008] and homozygous PlA1/PlA1 genotype [odds ratio = 8.8, (1.0-78.6, 95% confidence interval); P = 0.014]. Our results demonstrated that glycoprotein IIIa PlA1/PlA1 genotype carriers have a significantly increased risks of acute vascular ischemic events associated with a poor prognosis at 1 year. These postacute coronary syndrome patients might require an optimized secondary antithrombotic prophylaxis strategy. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors & Co-Authors
Addad, Faouzi
Tunisia, Monastir
Chu Fattouma-bourguiba
Εlalamy, Ismaïl Ismail
France, Paris
Sorbonne Université
Chakroun, Tahar
Tunisia, Sousse
Hopital Farhat Hached Sousse
Abderrazek, Fatma
Tunisia, Monastir
Chu Fattouma-bourguiba
Dridi, Zohra
Tunisia, Monastir
Chu Fattouma-bourguiba
Hamdi, Sonia
Tunisia, Monastir
Chu Fattouma-bourguiba
Hassine, Mohssen
Tunisia, Monastir
Chu Fattouma-bourguiba
France, Paris
Institut Pasteur, Paris
Ben-Farhat, Mohammed H.
Tunisia, Monastir
Chu Fattouma-bourguiba
Gerotziafas, Grigorios T.
France, Paris
Sorbonne Université
Hatmi, Mohamed
France, Paris
Sorbonne Université
Gamra, Habib
Tunisia, Monastir
Chu Fattouma-bourguiba
Statistics
Citations: 11
Authors: 11
Affiliations: 4
Identifiers
Doi:
10.1097/MBC.0b013e32833e47c1
ISSN:
09575235
Research Areas
Genetics And Genomics
Noncommunicable Diseases
Study Design
Cohort Study
Case-Control Study
Participants Gender
Male